iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Cipla to invest Rs 26 crore in Achira Labs' preference shares

16 May 2024 , 03:47 PM

Cipla stated on Wednesday that it has inked definitive agreements for an additional investment of up to ₹26 Crore in Achira Labs’ optionally convertible preference shares.

The investment will be made in four tranches, depending on the accomplishment of specified objectives. After the completion of the first tranche of investment, Cipla will own 27.27% of Achira’s voting rights.

In June 2022, Cipla paid ₹25 Crore for a 21.05% share in Achira Labs. Cipla stated that Achira has achieved tremendous progress in product development and R&D.

Achin Gupta, CEO, One India Business, Cipla, stated “The Company’s decision to infuse more funds in Achira is supported by its commitment to expand in the PoC diagnostics space.”

Gupta further said that Cipla’s strategic financing will enable Achira to commercially launch and further develop test panels.

Dhananjaya Dendukuri is the founder of Bengaluru-based Achira, which produces regulatory-approved medical diagnostic devices using microfluidic technology that requires only a small number of blood samples and chemicals.

Cipla primarily develops drugs to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and a variety of other medical diseases.

The Hamied family, the promoters of pharmaceutical giant Cipla, sold 2.53% of the company’s stock in a block deal to various investors on Wednesday, including Aditya Birla Sun Life Mutual Fund, and ICICI Prudential Mutual Fund, among others.

The ₹2,637 crore revenues will be used for “creating liquidity” for certain objectives, including philanthropy, the Mumbai-based drugmaker said in a regulatory filing. According to market records, ICICI Prudential Mutual Fund acquired shares worth ₹743 crore, while Aditya Birla Sun Life Mutual Fund purchased shares for ₹309 crore.

At around 12.58 PM, Cipla was trading 0.26% higher at ₹1,410.40 per piece, against the previous close of ₹1,406.70 on NSE. The counter touched an intraday high and low of ₹1,414.50, and ₹1,387.30, respectively.

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/

 

Related Tags

  • Achira Labs
  • Cipla
  • Cipla Investment
  • Cipla news
  • Cipla Stock
  • Cipla Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.